University of North Carolina at Chapel Hill

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial (2026) Mann JF, Marx N, Deanfield JE, Emerson SS, Inzucchi SE, McGuire DK, Mulvagh SL, et al. Journal article Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial (2026) Vaduganathan M, Green JB, Heerspink HJ, Kim SG, Mann JF, McGill JB, Mottl A, et al. Journal article Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial (2026) Agarwal R, Green JB, Heerspink HJ, McGill JB, Mottl A, Nangaku M, Rosenstock J, et al. Journal article Guidelines for Neuroprognostication in Critically Ill Adults with Status Epilepticus (2026) Madzar D, Rajajee V, Muehlschlegel S, Wartenberg KE, Alexander SA, Busl KM, Creutzfeldt CJ, et al. Journal article Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes (2026) Pop-Busui R, Rasmussen S, Deanfield JE, Buse JB, Marx N, Mulvagh SL, Inzucchi SE, et al. Journal article Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Nangaku M, et al. Journal article Activation mapping in multi-center retrospective rat sensory-evoked functional MRI datasets using a unified pipeline (2025) Galteau ME, Broadwater M, Chen Y, Desrosiers-Gregoire G, Gil R, Käßer J, Kim E, et al. Journal article Polygenic prediction of body mass index and obesity through the life course and across ancestries (2025) Smit RA, Wade KH, Hui Q, Arias JD, Yin X, Christiansen MR, Yengo L, et al. Journal article Combination effect of FInerenone and EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics (2025) Agarwal R, Green JB, Heerspink HJ, Mann JF, McGill JB, Mottl AK, Rosenstock J, et al. Journal article Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial (2025) Marx N, Deanfield JE, Mann JF, Arechavaleta R, Bain SC, Bajaj HS, Bayer Tanggaard K, et al. Journal article